NCT02468687View on ClinicalTrials.gov

NMP in Relapsed / Refractory Myeloma

PHASE1CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

August 20, 2015

Primary Completion Date

October 7, 2021

Study Completion Date

October 7, 2021

Conditions
Multiple Myeloma
Interventions
DRUG

N-methyl-pyrrolidone

NMP will be taken each morning as a single daily dose of oral suspension at a concentration of 50mg/ml on an empty stomach at least 30 minutes prior to food.

Trial Locations (1)

3002

Peter MacCallum Cancer Centre, Melbourne

Sponsors

Collaborators (1)

Melbourne Health
All Listed Sponsors
collaborator

Melbourne Health

OTHER

lead

Peter MacCallum Cancer Centre, Australia

OTHER